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Abstract:  It has been well-established that some adolescents diagnosed with attention-
deficit/hyperactivity disorder (ADHD) are at increased risk for cigarette smoking. Current 
research on the genetic basis of this association could ultimately translate into genetic tests 
capable of identifying smoking-prone adolescents with ADHD. In this study we examined 
81 ADHD affected adolescents’ (age 13–21) interest in genetic testing for nicotine addiction 
susceptibility. Fifty-seven percent of adolescents indicated a fair amount of interest or more 
in testing. Most adolescents indicated that the personal information revealed from testing 
would be either useful (29%) or interesting (37%). Implications for genetically-informed 
smoking prevention and cessation interventions in high risk adolescents with ADHD   
are discussed. 
Keywords:  attention-deficit/hyperactivity disorder (ADHD); genetic testing;   
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1. Introduction 
According to the National Survey on Drug Use and Health, approximately 27.6% of the U.S. 
population aged 12 years and older engages in tobacco use at least once per month [1]. Over three 
million of these users are minors—or roughly 12% of America’s adolescents [1]. Cigarettes are the 
most common form of tobacco use, and roughly 20% of teenagers currently smoke cigarettes [2]. 
Given the consequences of smoking, tobacco use is a major public health concern. It remains the 
leading cause of preventable deaths, responsible for at least 400,000 deaths annually, and is estimated 
to cost $82 million/year in lost productivity [3]. Most adult smokers began smoking when they were 
adolescents [4]. Thus, it is crucial to identify risk factors for smoking, and provide education, 
counseling, and interventions to prevent and/or stop smoking in adolescents who are most at risk [5]. 
One group of adolescents that has been identified to be at high risk for smoking is adolescents 
diagnosed with attention-deficit/hyperactivity disorder (ADHD) [6,7]. ADHD is a neurobehavioral 
syndrome that begins during childhood and affects approximately 3–5% of children and adolescents in 
the U.S. [8]. ADHD is characterized by symptoms of inattention and/or hyperactivity-impulsivity and 
impairment in the areas of home, school, and/or social functioning [8]. The increased risk for 
adolescents with ADHD to become smokers has been well-established through several studies. 
According to Lambert and Hartsough [9], by age 17 approximately 47% of adolescents diagnosed with 
ADHD report daily smoking as compared to 24% of adolescents without a diagnosis of ADHD. In 
another study, adolescents who display clinically significant symptoms of inattention, a major 
symptom of ADHD, are almost three times as likely as healthy adolescents to be current smokers [10]. 
Though the cause for this association remains unknown, it has been hypothesized that symptoms of 
ADHD, such as impulsivity, predispose adolescents to engage in a number of risky behaviors, 
including smoking [11]. Concomitant symptoms of ADHD, such as inattention, are also proposed to 
maintain smoking behavior due to the fact that nicotine has remediating/psychostimulating effects on 
attention, arousal, and concentration [6,12]. Indeed, preliminary studies with adults suggest that 
individuals who have been diagnosed with ADHD have less success in smoking cessation programs 
than adults without ADHD [13]. Despite this evidence, the only known smoking prevention program 
directly tailored to adolescents with ADHD was pharmacologically-based and proved ineffective [14]. 
At this time there is a need for more advanced (i.e., targeted and tailored) smoking interventions that 
address the biological, psychological, and social aspects of smoking initiation and cessation [15]. 
Numerous twin studies demonstrate that approximately 60%–70% of the variance in nicotine 
addiction may be attributable to inherited factors [16,17]. Thus, a burgeoning area of research has 
focused on both candidate gene approaches and genome-wide association study (GWAS) approaches 
to provide a more comprehensive perspective on the biological propensity for nicotine addiction. 
Briefly, candidate gene studies examine single genes that are hypothesized to influence the 
development of health concerns by contributing to a particular disease phenotype [18]. Several 
candidate genes have been proposed to be linked to smoking uptake and nicotine dependence. The 
impact of the cytochrome P450 CYP2A6 gene has gained prominence in the literature due to extensive 
replication  
studies [19,20]. Individuals with the wild genotype of CYP2A6 tend to metabolize nicotine faster, are 
more likely to be dependent on nicotine, and are more likely to relapse after an attempt to quit   Int. J. Environ. Res. Public Health 2010, 7 
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smoking [21]. Other genes shown to be associated with earlier smoking initiation and nicotine 
dependence include genes that code for nicotinic acetylcholine receptor (nACHr) subunits, the 
dopamine transporter gene (SLC6A3), the dopamine D3 and D4 receptor genes (DRD3, DRD4), and 
polymorphisms in a nicotine metabolizing enzyme gene CYP2A6 [21]. 
Whereas candidate gene studies focus on specific genes, GWAS examine the genome as a whole to 
assess the impact of multiple single nucleotide polymorphisms (SNPs) on health outcomes [22,23]. 
GWAS are usually exploratory in nature and advantageous in tobacco control research because they 
can provide information about previously studied genes and SNPs as well as novel genes and SNPs 
that have not yet been identified [22]. Furthermore, GWAS have the potential to clarify the interaction 
of genetic and environmental influences, such as low socioeconomic status, peer smoking, and 
maternal smoking, on smoking behavior [18]. Several GWAS have identified SNPs that may be related 
to cigarette smoking behaviors. Although a complete review of those works is well-beyond the scope 
of this article, several intriguing findings are noteworthy. For example, there is preliminary evidence 
that polymorphisms in the CHRNA3-CHRNA5 nicotinic receptor subunit gene cluster are related to 
cigarette use per day [24], and in the gene NRXN1 are related to nicotine dependence [25,26]. SNPs 
that play a role in glutamate (a neurotransmitter) signaling, such as in genes GRIN2B, GRIN2A, 
GRIK2, and GRM8, are elevated after nicotine administration, suggesting they may affect vulnerability 
to smoking initiation and maintenance [27]. Specific SNPs have also been associated with success in 
stopping smoking, including those in genes ATP1BL1,  CSMD1,  DDX10, DSCAM,  FLJ22746, 
RPL21P12, and SLC9A9 [27-30]. Studies indicate that the SNPs/variants for CNTN6,  CSMD1, 
LRRN6C, and SEMA3C are associated with vulnerability to substance addiction as well [31,32]. 
One outgrowth of these discoveries may be the advent of predictive genetic tests of nicotine 
addiction susceptibility [33]. Genetic testing for nicotine addiction susceptibility would allow health 
care providers to identify those adolescents at greatest risk for smoking [34,35]. Given the high rate of 
smoking among adolescents with ADHD, genetic testing may offer an additional strategy to reduce 
smoking risk by motivating adolescent behavior change [36]. Genetic information could help target 
adolescents with ADHD who are at high risk for smoking and enable health care providers to tailor 
interventions to address both the adolescent’s genetic and neurobehavioral predispositions to smoke 
(i.e., by inhibiting genes that make smoking more likely and addressing symptoms of ADHD such as 
impulsivity) [37,38]. Adolescents who are knowledgeable about their genetic nicotine addiction 
susceptibility may be more motivated to refrain from smoking or make an effort to stop smoking. 
Physicians support the notion that knowledge of personal nicotine addiction susceptibility could 
motivate patients to quit smoking [39] and indicate interest in using genetic testing to match patients to 
optimized smoking cessation strategies [40]. Pharmacogenetic studies have begun elucidating which 
persons may have the most success with nicotine replacement treatments for stopping smoking [41], 
and this promising approach could be adapted for primary prevention as well. 
Preliminary evidence suggests adolescents are interested in learning about their genetic risk for a 
wide range of health conditions. Studies on genetic testing for several health concerns, including   
adult-onset breast cancer, Tay-Sachs disease, hypercholesterolemia, osteoporosis, hemachromatosis, 
heart disease, and nicotine addiction, show that a majority of adolescents are interested in receiving 
genetic information regarding their personal risk [36,42-45]. These studies indicate that adolescents 
with a family member who has the target condition (such as breast cancer), or who are members of Int. J. Environ. Res. Public Health 2010, 7 
 
 
1697
ethnic groups with a higher risk of a disorder (such as Tay-Sachs disease), and/or who perceive the 
condition to be severe tend to be most interested in genetic testing [43]. 
With respect to nicotine addiction susceptibility testing, Tercyak and colleagues [36] found that 
approximately 62% of general population adolescents attending routine medical appointments would 
be interested in this form of genetic testing if it became available. Interest tended to be associated with 
higher socioeconomic status and better school performance. When asked to clarify reasons for their 
level of interest, 30% of adolescents wanted the information because it would directly affect their 
efforts to prevent or stop smoking. This suggests that nicotine addiction susceptibility test results may 
be a motivator for adolescents to alter their smoking intentions and practices. However, although this 
study provided significant information regarding the attitudes of adolescents in the general population, 
the sample did not include adolescents diagnosed with ADHD. It is crucial to assess the attitudes of 
adolescents with ADHD towards nicotine addiction susceptibility testing in particular because they are 
at increased smoking risk. 
The purpose of the present study was to determine the interest of adolescents with ADHD in 
nicotine addiction susceptibility testing and to clarify adolescents’ reasons for their level of interest in 
such testing. It also sought to identify if adolescent smoking behavior was positively related to interest. 
Consistent with the results of the Tercyak and colleagues’ study [36], we hypothesized that the 
majority of adolescents with ADHD would be interested in this form of predictive genetic testing. We 
approached this issue by sampling affected adolescents presenting for clinical care of their ADHD 
symptoms, and administering a self-reported behavioral assessment of key constructs of interest (see 
Experimental Section for complete details). Data were analyzed descriptively by employing univariate 
statistical procedures, followed by a bivariate analysis of the relationship between adolescent smoking 
behavior and interest in genetic testing. 
2. Results and Discussion 
2.1. Interest in Genetic Testing 
Most adolescents in this sample expressed interest in genetic testing (see Figure 1). Fifty-seven 
percent of the sample indicated a fair amount of interest or more. 
Figure 1. Adolescents’ interest in nicotine addiction susceptibility testing (n = 87). 
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2.2. Reasons for Interest in Genetic Testing 
The reasons that adolescents provided for their level of interest in genetic testing were classified 
into five categories based on their indication that participation in testing would be: (1) useful, as it 
would likely affect their smoking decision making and smoking behavior, (2) generally interesting, but 
unlikely to impact upon decision making about smoking or smoking behavior, (3) irrelevant, (4) 
unimportant, or (5) other. The coding scheme achieved high inter-rater reliability among the two 
independent raters (Cohen’s κ = 0.98); any discrepancies in coding were resolved by consensus. 
Out of the overall sample of 87 participants, 68 (78%) adolescents provided clarifying information 
regarding the reason for the strength of their interest in genetic nicotine addiction susceptibility testing 
(see Table 1). There were no differences between participants who did and did not elaborate upon their 
responses based on age or gender; however, non-Caucasian adolescents were less likely to elaborate 
than were Caucasian adolescents (62% vs. 85%), χ
2 (1) = 6.00, p = 0.014. Most adolescents indicated 
that the personal information to be gained from genetic testing would be either useful (n = 20, 29%) 
and would directly affect smoking cessation/prevention, or interesting (n = 25, 37%) and would 
indirectly affect smoking cessation/prevention. Fewer adolescents reported that the personal 
information to be gained from genetic testing would be either irrelevant (n = 9, 13%) due to their self-
proclaimed nonsmoking status, or otherwise unimportant (n = 12, 18%). 
Table 1. Adolescents’ elaborated reasons behind the strength of their interest in nicotine 
addiction susceptibility testing (n = 68). 
Reason Description  n  %
Interesting 
Indication of a general/nonspecific interest in, or curiosity about, personal 
information that would be learned as a result of participation in testing without 
any expressed behavioral intent (e.g., altruistic, ‘a test/result is good to know 
for the future,’ ‘curious for future generations’) 
25 37
Useful 
Indication of a specific interest in, or curiosity about, personal information 
that would be learned as a result of participation in testing with the expressed 
intent of preventing smoking behavior or stopping smoking (e.g., risk 
avoidance, active maintenance of current/future health) 
20 29
Irrelevant 
Indication that personal information that would be learned as a result of 
participation in testing is irrelevant due to self-proclaimed nonsmoking status 
(e.g., ‘a test/result doesn’t matter because I will never smoke’) 
9 13
Unimportant 
Indication that personal information that would be learned as a result of 
participation in testing is generally unimportant, uninteresting, or insignificant 
(e.g., ‘a test/result would not affect my decisions,’ ‘it is not useful’) 
12 18
Other  Miscellaneous (e.g., references to familial cancer, ‘just because,’ other 
inexplicable responses)  2 3 
2.3. Association with Smoking Behavior 
Finally, we explored whether or not interest in nicotine addiction susceptibility testing was 
associated with whether or not the adolescent with ADHD had ever smoked cigarettes. A Student’s  
t-test was used to compare the mean scores of ever smokers (M = 2.59, SD = 1.07) vs. never smokers 
(M = 2.70, SD = 1.13) and this result was not significant, t (85) = −0.46,  p = 0.64. Additional Int. J. Environ. Res. Public Health 2010, 7 
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independent variables, such as participant age, gender, race, and income, were examined as well. 
However, the findings were less robust than those presented herein (data not shown). 
2.4. Summary and Interpretation 
This study investigated the extent to which adolescents diagnosed with ADHD would be interested 
in genetic testing for nicotine addiction susceptibility if it were available and offered to them. It also 
assessed adolescents’ reasons for their level of interest and other key variables. Results indicated that 
most adolescents would be interested in nicotine addiction susceptibility testing and that the 
information to be gained from genetic testing would either directly or indirectly affect adolescents’ 
smoking cessation/prevention efforts--independent of their cigarette smoking history. Adolescents’ 
expressed desire to know their risk for nicotine addiction was related to their desire to lead a   
smoke-free life (e.g., “If I was at a greater risk for becoming addicted [to cigarettes] I’d go out of my 
way to avoid the temptation.”) or curiosity about personal health information (e.g., “I would want to 
know and be aware of anything that could happen to me.”). 
The current study’s findings are similar to two previous studies reporting that adolescents in the 
general population and those coping with a chronic disease were interested in nicotine addiction 
susceptibility testing [36,45]. The current study is unprecedented in that it assessed interest in genetic 
testing for nicotine addiction susceptibility among adolescents with ADHD—a population that is at 
high risk for smoking cigarettes. To our knowledge, few works have assessed genetic testing interest 
among children and adolescents who were at high risk for a specific health concern (i.e., heart disease 
or breast cancer) [42]. Furthermore, only one other study investigated the potential impact of genetic 
testing on specific adolescent health behavior [36]. The distinctive information provided by the current 
study is that many high risk adolescents with ADHD are interested in genetic susceptibility testing, 
and believe the results of this genetic test would affect their smoking behavior. This was true 
regardless of previous smoking behavior, indicating that genetic susceptibility testing may have an 
impact on both smoking uptake and smoking cessation. The results provide early/preliminary support 
for continuing research regarding genetic biomarkers for risk of nicotine addiction in high priority 
populations. 
The importance of increasing our knowledge regarding nicotine addiction susceptibility biomarkers 
cannot be overstated. Research has consistently demonstrated that adolescents with ADHD are more 
likely to smoke cigarettes than healthy adolescents [9]. Symptoms of ADHD (i.e., impulsivity and 
inattention) have been proposed to impact the likelihood that an adolescent will try cigarettes and 
become addicted to nicotine [6,12]. However, there may be additional predisposing factors that have 
not yet been discovered, such as common genetic etiology for both ADHD and nicotine addiction. 
Increased information regarding the underlying genetic aspects of these two disorders could potentially 
provide a greater understanding of the mechanisms leading to both ADHD and nicotine addiction. This 
may one day translate into genetic tests capable of identifying adolescents with ADHD who are prone 
to developing smoking habits. 
There are potential long-term clinical implications for the identification and use of nicotine 
addiction susceptibility biomarkers as well. Extensive evidence indicates that pharmacological 
interventions are a key component of the treatment of ADHD symptoms [46] and individuals Int. J. Environ. Res. Public Health 2010, 7 
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diagnosed with ADHD have less success in smoking cessation programs than individuals without 
ADHD [13]. The identification of addiction susceptibility biomarkers may allow researchers to 
develop pharmacological treatments that concurrently address both ADHD symptoms and nicotine 
addiction risk. Furthermore, health care providers may be able to use genetic screening to tailor 
interventions and optimize care in order to address adolescents’ symptoms from a more comprehensive 
biopsychosocial approach. Given the staggering number of annual deaths and millions of dollars per 
year of lost productivity related to tobacco use [3] and the high risk for nicotine addiction among 
individuals with ADHD, the potential benefits of nicotine addiction-related genetic research are vast.  
Despite the possible gains of nicotine addiction susceptibility testing, there are also recognized 
caveats. As noted earlier, many questions about the relationship between ADHD and nicotine 
addiction remain unanswered, especially those examining causal mechanisms of action. It would be 
prudent for researchers to continue to examine this relationship, with an eye toward common genetic 
and/or environmental etiologies for both traits, both alone and in combination with one another. 
Furthermore, genetic susceptibility testing is not a panacea for future health concerns. There is scant 
evidence that providing individuals with information about risk biomarkers reduces smoking behavior, 
and there may be unforeseen consequences to such testing. For example, individuals who are known to 
be at normal risk of nicotine addiction may be encouraged to smoke or deterred from seeking cessation 
programs [47]. Although unlikely, this possibility should be explored in future studies. Alternatively, 
individuals with a higher risk of smoking may believe that smoking prevention or cessation programs 
will not be successful because they are “destined” to be addicted to nicotine. Additionally, genetic 
testing for a disorder is not as clear-cut as it may have once seemed. Many genes are pleiotropic in 
nature, meaning they influence multiple phenotypic traits. Genes that are associated with the dopamine 
transporter system, one of several predominant gene systems being studied with respect to nicotine 
addiction, are related to other mental health conditions as well [48]. Information about nicotine 
addiction risk or ADHD could reveal information about other potential health outcomes. Finally, there 
are a variety of ethical considerations as well, such as the stigma that may result from a societal view 
of nicotine addiction as a medical problem relative to other addictive disorders [49]. Thus, researchers 
and health care providers need to consider an array of ramifications prior to using genetic screening 
with clinical populations. Continued research about the consequences of genetic testing is warranted. 
3. Experimental Section 
Demographic characteristics of the 87 participants in this study are provided in Table 2. 
Participants were 87 healthy adolescents between the ages of 13 and 21 (M = 16.64, SD = 2.17) 
who had been diagnosed with ADHD; 43% of the sample was male. Participants were recruited for 
this study upon attending a general medical check-up at an adolescent medicine clinic in an urban 
ambulatory care center. Adolescents were eligible for this study if they were: (1) within the specified 
age range, (2) able to read and comprehend English, (3) able to provide valid informed consent/assent, 
(4) in good general health as determined by parental or self-report, and (5) had a confirmed diagnosis 
of ADHD. ADHD diagnoses were determined by parental report with a structured interview [50], 
clinician report based on standard psychiatric diagnostic criteria [8], and medical record review. 
Participants’ current symptoms were confirmed using an ADHD behavior rating scale [50]. Int. J. Environ. Res. Public Health 2010, 7 
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Table 2. Demographic characteristics (n = 87). 
Variable/level Mean  (SD) or n (%)
Age, in years  16.64 (2.17) 
Gender  
 Male  37  (43) 
 Female  50  (57) 
Race  
 Caucasian  61  (70) 
  African American 14 (16) 
 Hispanic  7  (8) 
 Other  5  (6) 
Income, in $  72,452 (23,404) 
Lifetime smoking   
 No  41  (47) 
 Yes  46  (53) 
 
Potential participants were screened by research assistants who attended the adolescent medicine 
clinic at predetermined times. Research assistants directly approached adolescents who were 18 years 
of age and older. Parents/legal guardians of adolescents who were under 18 years of age were 
approached by research assistants prior to speaking with the adolescent. Once written consent/assent 
was obtained, participants completed a self-administered behavioral survey, provided a DNA sample 
in order for genes hypothesized to relate to smoking behavior to be isolated, and underwent a 
biochemical verification test of recent cigarette smoking (exhaled carbon monoxide). Participants were 
informed that they would not receive the results of their genetic test because clinical genetic testing for 
nicotine addiction susceptibility is not yet available. Participants received a small incentive as an 
acknowledgement of their time. There was an approximate 88% participation rate in the study, and the 
majority of adolescents who declined to participate did so due to a reported lack of time. 
Demographic variables: age, gender, and race data were collected from each participant. 
Participants’ home address was used to create an area-based socioeconomic measure (via conversion 
of zip code to median household income [a mid-point division of income into equal groups]) [51]. This 
approach is commonly used in behavioral epidemiologic investigations designed to understand 
multilevel influences on clinical health outcomes (e.g., environmental resources, risk and protective 
factors) [52]. 
Smoking status: participants’ smoking status was determined by their response to several standard 
epidemiological questions regarding experimentation with smoking, number of cigarettes smoked 
throughout one’s life, and the amount of time that had passed since the participant last smoked [53]. 
Interest in nicotine addiction susceptibility testing: the dependent variable for this study was 
participants’ interest in a hypothetical genetic test for nicotine addiction susceptibility. Participants’ 
responded to the following item on a 4-point Likert scale (1 = Not at all to 4 = A lot): “Someday, 
scientists may be able to predict who is at greater risk for growing up to become addicted to smoking, 
based on a person’s genes (their DNA). If this information were available, how strongly would you be 
interested in learning about your genetic risk for developing a smoking habit?” An open-ended 
question clarifying the rationale of the adolescents’ interest in genetic testing followed the item. These Int. J. Environ. Res. Public Health 2010, 7 
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responses were then content-coded by two independent raters using a previously developed coding 
scheme [36]. 
4. Conclusions 
There are several limitations to this study. First, the current investigation’s sample size was modest 
and affected our ability to conduct additional statistical analyses. Second, the majority of adolescents 
in this sample were Caucasian and from moderately-resourced families. The extent to which 
adolescents of other backgrounds might be interested in genetic testing for nicotine addiction 
susceptibility is not known; further study with more representative samples is also necessary. Third, 
adolescents who participated in this study consented to provide a DNA sample to identify genes 
related to nicotine addiction. This may have led to positive bias among participants’ responses to the 
primary outcome of interest. And finally, a single-item measure was used to assess adolescents’ 
interest in genetic testing. It is advised that future studies expand on this approach. Despite these 
limitations, the work provides novel information about a population that is well-documented to be at 
increased risk for nicotine addiction. These preliminary data may lead to further research regarding 
adolescents with ADHD, nicotine addiction, and genetic testing. 
Over the last decade, interest in, and applications for genetic testing have expanded greatly [54]. 
The human genome can now be sequenced and specific markers for future health disorders are rapidly 
being identified. The practice of medicine is increasingly becoming personalized, with greater 
emphasis on risk prediction and targeted and tailored interventions [55,56]. The present study provides 
preliminary evidence that adolescents with ADHD, a high risk population for developing nicotine 
addiction, are interested in genetic screening if available, suggesting that it would be prudent for 
researchers to continue researching genetic biomarkers for nicotine addiction susceptibility and 
ADHD. This research has the potential to provide novel information about the relationship of ADHD 
and nicotine addiction and may lead to better identification of adolescents who are at high risk for 
smoking and enhanced smoking prevention/cessation programs. Presently, it will be important for 
researchers, health professionals, and public health specialists to consider both the positive and 
negative ramifications of genetic testing and proceed with caution. Future studies regarding the ethical 
implications of genetic testing should be conducted prior to incorporating this approach into health  
care interventions. 
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